McKesson Tops S&P with 59% Rally; Price Targets Raised to $1,012 and $966
McKesson shares have rallied 59% over the past year and 15% year-to-date following strong pharmaceutical and cancer segment results. TD Cowen lifted its price target to $1,012 and Morgan Stanley to $966, both maintaining positive ratings after the latest earnings beat.
1. Share Performance and Market Position
McKesson’s stock has surged 59% over the last 12 months and 15% year-to-date, positioning the company as one of the top performers in the S&P index following its latest quarterly report.
2. Analyst Upgrades and Price Target Raises
TD Cowen boosted its price target from $1,000 to $1,012 and maintained a Buy rating, while Morgan Stanley raised its target to $966 from $916 and kept an Overweight stance after reviewing the company’s earnings.
3. Business Segment Performance
The pharmaceutical distribution unit and oncology services division delivered robust revenue growth and margin expansion, with management highlighting resilience in high-demand therapies and cost control amid elevated industry expectations.
4. Cramer Endorsement
Television host Jim Cramer praised McKesson’s market influence, stating it has outperformed political headwinds and is ‘more powerful than President Trump,’ a remark that has amplified investor enthusiasm around the stock.